Antioxidant and pro-oxidant capacity of catecholamines and related compounds. Effects of hydrogen peroxide on glutathione and sphingomyelinase activity in pheochromocytoma PC12 cells: Potential relevance to age-related diseases

Journal of Neural Transmission

Volumn 108, Issue 5, 2001, Pages 541-557

  Sofic, E ^a,b   Denisova, N ^a   Youdim, K ^a   Vatrenjak Velagic, V ^c   De Filippo, C ^c   Mehmedagic, A ^c   Causevic, A ^c   Cao, G ^a   Joseph, J A ^a   Prior, R L ^a  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NONE

Author keywords

Antioxidant; Catecholamines; Dopamine; Glutathione; Oxygen radical absorbance capacity (ORAC) assay; Parkinson's disease; Pro oxidant; Sphingomyelinase

Indexed keywords

2,2' AZOBIS(2 AMIDINOPROPANE); AMINO ACID; CATECHOLAMINE DERIVATIVE; COPPER; DOPAMINE; GLUTATHIONE; HYDROGEN PEROXIDE; NORADRENALIN; OXYGEN RADICAL; SCAVENGER; SPHINGOMYELIN PHOSPHODIESTERASE;

ABSORPTION SPECTROPHOTOMETRY; AGING; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL LEVEL; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; NONHUMAN; OXIDATIVE STRESS; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL ASSAY; CATECHOLAMINES; CERAMIDES; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICALS; GLUTATHIONE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; NEURODEGENERATIVE DISEASES; OXIDANTS; OXIDATIVE STRESS; PC12 CELLS; PEROXIDES; RATS; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELINS;

EID: 0035039619     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020170055     Document Type: Article

References (53)

1. Adams JD, Odunze IN (1991) Oxygen free radicals and Parkinson's disease. Free Radic Biol Med 10: 161-169
2. Beal MF (1997) Oxidative damage in neurodegenerative disease. Neuroscience 3: 21-27
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson's and Huntington. J Neurol Sci 20: 415-455
4. Birkmayer W, Hornykiewicz O (1961) Der Dioxyphenylalanin (=L-DOPA) Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787-788
5. Cao G, Verdon C, Wu AHB, Wang H, Prior RL (1995) Automated oxygen radical absorbance capacity assay using the COBAS FARA II. Clin Chem 41: 1738-1744
6. Cao G, Sofic E, Prior RL (1996) Antioxidant capacity of tea and common vegetables. J Agric Food Chem 44: 3426-3431
7. Cao G, Sofic E, Prior RL (1997) Antioxidant and pro-oxidant behavior of flavonoids: structure-activity relationships. Free Radic Biol Med 22: 749-760
8. Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxytyramine in brain. Science 127: 471
9. Carr A, Frei B (1999) Does vitamin C act as pro-oxidant under physiological condition? Faseb J 13: 1007-1024
10. Cohen G (1987) Monoamine oxidase, hydrogen peroxide and Parkinson's disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 119-125
11. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet ii: 1219-1220
12. Dexter DT, Carter C, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389
13. Ebadi M, Srinivasan SK, Baxi MD (1996) Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol 48: 1-19
14. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38: 1236-1239
15. Gerlach M, Riederer P (1996) Pathogenesis and neuroprotective therapy trial in chronic degenerative diseases. Status of antioxidants. Med Klin 91(3): 163-170
16. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63(4): 793-807
17. Gerlach M, Riederer P, Youdim MB (1996) Molecular mechanism for neurodegeneration. Synergism between reactive oxygen species, calcium, and exicototoxic amino acids. Adv Neurol 69: 177-194
18. Gottfries CG, Karlsson I, Svennerholm L (1996) Membrane components separate early-onset Alzheimer" disease from senile dementia of the Alzheimer type. Int Psychogeriatr 8(30): 365-372
19. Götz M, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress: free radical production in neural degeneration. Pharmac Ther 63: 37-122
20. Götz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, Riederer P, Gerlach M (2000) Alterd redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm 107: 41-48
21. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643
22. Halliwell B (1989) Oxidants and central nervous system: some fundamental questions. Acta Neurol Scand 126: 23-33
23. Hanasaki Y, Ogawa S, Fukui S (1994) The correlation between active oxygen scavenging and antioxidative effects of flavonoids. Free Radic Biol Med 16: 845-850
24. Jenner P, Shapira AHV, Marsden CD (1992) New insights into the cause of Parkinson's disease. Neurology 42: 2241-2250
25. Kerry N, Rice-Evans C (1999) Inhibition of peroxynitrite-mediated oxidation of dopamine by flavonoid and phenolic antioxidants and their structural relationships. J Neurochem 73: 247-253
26. Kienzl E, Eichinger K (1988) Preparation of dopamine 3-O-sulfate and dopamine 4-O-sulfate as reference substances and high performance liquid Chromatographic trace determination. J Chromatogr 430: 263-269
27. Lin AMY, Ho LT (2000) Melatonin suppresses iron-induced neurodegeneration in rat brain. Free Radic Biol Med 28: 904-911
28. Liu B, Hannun YA (1997) Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 272: 16281-16287
29. Liu J, Mori A (1993) Monoamine metabolism provides an antioxidant defense in the brain against oxidant and free radical-induced damage. Arch Biochem Biophys 302: 118-127
30. Marsden CD, Olanow CW (1998) The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann Neurol [Suppl] 44: S189-S196
31. Miller JW, Selhub J, Joseph JA (1996) Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of 0-methylation and melatonin. Free Radic Biol Med 21: 241-249
32. Olanow CW (1992) An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 32: S2-S9
33. Olanow CV, Jenner P, Beal MF (1998) Cell death and neuroprotection in Parkinson's disease. Ann Neurol [Suppl] 44: S1-S196
34. Pieri C, Marra M, Moroni F, Recchioni R, Marccheselli F (1994) Melatonin: a peroxyl radical scavenger more effective than vitamin E. Pharmacol Lett 55: 271-276
35. Reichmann H, Riederer P (1989) Biochemische Analyse der Atmungskettenkomplexe verschiedener Hirnregionen von Patienten mit Morbus Parkinson und andere Basalganglienerkrankungen. Symposium zu einem Förderschwerpunkt des BMFT, Bad Kissingen, 23.-25. April, S44
36. Rice-Evans CA, Miller NJ, Paganga G (1996) Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 20: 933-956
37. Riederer P, Umek H (1985) L-Dopa-Substitution der Parkinson-Krankheit. Geschichte-Gegenwart-Zukunft. Springer, Wien New York
38. Riederer P, Rausch WD, Schmidt B, Kruzik P, Konradi C, Sofic E, Danielczyk W, Fischer M, Ogris E (1988) Biochemical fundamentals of Parkinson's disease. Mt Sinai J Med 55: 21-28
39. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brain. J Neurochem 52(2): 515-520
40. Rapta P, Misik V, Stasko A, Vrabel I (1995) Redox intermediates of flavonoids and caffeic acid-esters from propolis: an EPR-spectroscopy and cyclic voltametry study. Free Radic Bio Med 18: 901-908
41. Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K (1959) Distribution of catechol compounds in human brain. Biochem Biophys Acta 32: 586-587
42. Sian J, Gerlach M, Riederer P (1998) The role of altered glutathione status in the development of Parkinson's disease. In: Shaw C (ed) The role of glutathione in the central nervous system. Taylor & Francis, Bristol, pp 287-304
43. Sian J, Gerlach M, Youdim MB, Riederer P (1999) Parkison's diesease: a major hypokinetic basal ganglia disorder. J Neural Transm 106: 443-476
44. Singh I, Pahan K, Khan M, Singh AK (1998) Cytokine-mediated induction of ceramide production is redox sensitive. Implication to proinflammatory cytokine-mediated apoptosis in demyelinating diseases. J Biol Chem 273(32): 20354-20362
45. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199-205
46. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brain. J Neurochem 56: 978-982
47. Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142: 128-130
48. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Natl Acad Sci USA 88: 1398-1140
49. 2 detoxification in LPS-activated hepatic endothelial and Kupffer cells. Am J Physiol 273(6Pt 1): G1304-1311
50. Tan DX, Chen LD, Poggeler B, Manchester LC, Reiter RJ (1993) Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1: 57-60
51. Tse DC, McCreery RL, Adams RN (1976) Potential oxidative pathways of brain catecholamines. J Med Chem 19: 37-40
52. Yen G-Ch, Hsieh Ch-L (1997) Antioxidant effect of dopamine and related compounds. Biosci Biotech Biochem 57(1): 115-116
53. Youdim MBH, Ben Shachar D, Riederer P (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand 26: 47-54